secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0001564590-22-015295
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma enters into $65M at-the-market offering agreement with Jefferies, terminates prior JonesTrading ATM
--------------------------------------------------------------------------------

- aTyr Pharma entered into Open Market Sale Agreement with Jefferies LLC to sell up to $65M of common stock at market prices on Nasdaq.
- The agreement includes a 3.0% commission to Jefferies on gross proceeds from each sale of shares.
- Company terminated the prior Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC dated March 23, 2021.
- Prior agreement allowed up to $25M in common stock sales through JonesTrading as sales agent.
- Shares will be sold under existing shelf registration statement (File No. 333-250095) effective November 23, 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022015295/0001564590-22-015295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022015295/life-8k_20220422.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-015295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer